Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
77.50    3.00 (3.95%)
Bid:
77.00
Ask:
78.00
Spread: 1.00 (1.299%)
Market Cap: £370.15m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Interim Results

28 Jan 2005 16:48

Readybuy PLC28 January 2005 READYBUY PLC (the "Company") UNAUDITED INTERIM RESULTSFor the six months ended 31 October 2004 Chairman's Statement During the period under review, the Company has successfully secured several newlistings for its products with supermarkets. We have also started to produce ourproducts in reasonable volumes and now distribute to a number of customers bothon a regional and national basis. Certain lines have been listed on apromotional basis to build customer awareness. Results Turnover in the period under review was £139,000 producing a loss before tax of£138,000 and a loss per share of 0.8p As at 31 October 2004, the Group had net cash of approximately £51,000. Our monthly cash burn has been substantially reduced during this same period. Strategy We continue to pursue our stated strategy of developing a top quality range ofchilled ready meals both in the retail and food service sectors. We also intendto develop other products which will complement the existing portfolio. Staff As the business has grown, all our staff have worked extremely hard to meetcustomer requirements and I would like to thank them for all their efforts Prospects Since the half-year, we have been working on several new listings which have notyet been confirmed. Accordingly, the Directors believe that the results for thefull year will fall below market expectations. The board is currently reviewing its working capital requirements and may seekto raise additional equity to invest further in the business and to fund theGroup through to profitability. Colin DaviesNon Executive Chairman- READYBUY PLCGROUP PROFIT AND LOSS ACCOUNTfor the six months ended 31 October 2004 Unaudited Audited Unaudited 6 months Period Period to 29/04/03 to 29/04/03 to 31/10/2004 30/04/2004 31/10/2003 £'000 £'000 £'000 TurnoverContinuing operations 139 19 0 Operating lossContinuing operations (137) (343) (114) Loss on ordinary activities before interest (137) (343) (114) Net interest (1) 0 0 Loss before taxation (138) (343) (114) Taxation 0 45 0 Loss after taxation (138) (298) (114) Dividends 0 0 0 Retained loss (138) (298) (114) Loss per shareBasic and diluted (0.8p) (2.2p) (1.2p) Dividends per share 0 0 0 READYBUY PLCGROUP BALANCE SHEETat 31 October 2004 Unaudited Audited Unaudited 31/10/2004 30/04/2004 31/10/2003 £'000 £'000 £'000 Fixed assetsGoodwill 629 646 671Tangible assets 208 218 212 837 864 883 Current assetsStock 17 7 0Debtors 116 82 52Cash at bank 276 429 659 409 518 711 Creditors falling due within one year (334) (323) (328) Net current assets 75 195 383 Total assets less current liabilities 912 1,059 1,266 Creditors falling due after one year (16) (25) (46) 896 1,034 1,220Capital and reservesCalled up share capital 90 90 90Share premium account 1,242 1,242 1,244Profit and loss account (436) (298) (114) Equity shareholders' funds 896 1,034 1,220 READYBUY PLC GROUP CASHFLOW STATEMENT for the six months ended 31 October 2004 Unaudited Audited Unaudited 6 months Period Period to 29/04/03 29/04/03 to to 31/10/2004 30/04/2004 31/10/2003 £'000 £'000 £'000 Operating loss (137) (343) (114) Depreciation and amortisation 33 82 42 Movement in working capital (17) (146) (163) Net cash outflow from operating activities (121) (407) (235) Net cash outflow from capital expenditure and financial investment (6) (42) (12) Purchase of subsidiary undertaking expenses and flotation - (272) (270) expenses Overdraft, net of cash, acquired with subsidiary undertaking - (6) (6) Net cash outflow from acquisitions and disposals - (278) (276) Net cash outflow before use of liquid resources and financing (127) (727) (523) Repayment of term loans - (220) (220) Capital element of finance lease payments (25) (19) (8) Issue of ordinary share capital net of redemption - 1,169 1,169 Net cash (outflow)/inflow from financing (25) 930 941 (Decrease)/Increase in cash in the period (152) 203 418 Analysis of net funds Cash at bank and in hand 276 429 659 Overdraft (225) (226) (241) 51 203 418 Debt repayable by instalments: Due within one year (18) (34) (24) Due after more than one year (16) (25) (46) (34) (59) (70) 17 144 348READYBUY PLCINTERIM ACCOUNTSfor the six months ended 31 October 2004 Notes 1 The unaudited results for the six month period have been prepared on a basis consistent with the accounting policies disclosed in the Group's 2004 accounts and do not constitute statutory accounts within the meaning of Section 240 of the Companies Act 1985 2 The figures for the period ended 30 April 2004 have been extracted from the statutory accounts which have been delivered to the Registrar of Companies and received an unqualified audit report. 3 The calculation of the loss per share for the period is based on the loss after taxation divided by the average number of ordinary shares in issue, being 17,994,010 (31 October 2003 9,295,367 and 30 April 2004 13,585,434). This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
21st Jan 20207:00 amRNSDirector Appointment
8th Jan 20207:00 amRNSAvacta and Daewoong Establish Joint Venture
26th Nov 20199:00 amRNSHolding(s) in Company
22nd Nov 20198:41 amRNSDirector/PDMR Shareholding
13th Nov 20197:00 amRNSLG Chem Life Sciences Expands Partnership
11th Nov 20197:00 amRNSHolding(s) in Company
8th Nov 20196:30 pmRNSHolding(s) in Company
8th Nov 20196:26 pmRNSHolding(s) in Company
7th Nov 20191:00 pmRNSHolding(s) in Company
7th Nov 201911:00 amRNSHolding(s) in Company
6th Nov 20192:30 pmRNSHolding(s) in Company
4th Nov 20191:18 pmRNSResult of General Meeting
18th Oct 201912:06 pmRNSProposed Placing & Subscription to raise up to £9M
18th Oct 201912:05 pmRNSInterim Results for the Period Ended 31 July 2019
10th Oct 20197:00 amRNSCollaboration with ADC Therapeutics
5th Aug 20199:05 amRNSSecond Price Monitoring Extn
5th Aug 20199:00 amRNSPrice Monitoring Extension
29th Jul 20197:00 amRNSAvacta's CEO to Present at Biotech Investor Day
20th Jun 20197:00 amRNSAvacta and Selexis Partner to Develop Cell Line
19th Jun 20197:00 amRNSTurner Pope Investor Evening
12th Jun 20197:00 amRNSAvacta's CSO to Present at Major US Conference
10th Jun 20197:00 amRNSAvacta hits Clinical Candidate Selection Milestone
3rd Jun 20197:00 amRNSTMAC Programme Accelerates
23rd Apr 20193:48 pmRNSIssue of Equity
12th Apr 20192:46 pmRNSHolding(s) in Company
9th Apr 20197:00 amRNSInterim Results
8th Mar 201912:14 pmRNSIssue of Equity
6th Feb 201912:27 pmEQSHardman & Co Research: Avacta (AVCT): A second wake-up call for the market
4th Feb 20197:00 amRNSModerna Exercises Exclusive Product License Option
28th Jan 20197:00 amRNSDirector Appointment
21st Jan 20193:40 pmRNSResult of Annual General Meeting
21st Jan 20197:00 amRNSAGM Business Update and Notice of Results
18th Jan 20195:08 pmRNSShare Incentive Plan/Issue of Equity
9th Jan 201911:06 amRNSHolding(s) in Company
7th Jan 20192:50 pmRNSDirector/PDMR Shareholdings
3rd Jan 20198:56 amRNSHolding(s) in Company
2nd Jan 20197:00 amRNSDirector/PDMR Shareholding
21st Dec 20181:41 pmRNSHolding(s) in Company
19th Dec 20183:32 pmRNSHolding(s) in Company
17th Dec 20187:00 amRNSAvacta London Science Day
12th Dec 201812:50 pmRNSHolding(s) in Company
12th Dec 201812:44 pmRNSHolding(s) in Company
12th Dec 20187:00 amRNSAppointment of Chief Medical Officer
11th Dec 20187:00 amRNSPosting of Annual Report and Notice of AGM
10th Dec 20182:05 pmRNSSecond Price Monitoring Extn
10th Dec 20182:00 pmRNSPrice Monitoring Extension
10th Dec 20187:30 amEQSHardman & Co Research: Avacta (AVCT): Wake-up call for the market
10th Dec 20187:00 amRNSDevelopment Partnership with LG Chem Life Sciences
12th Nov 20187:00 amRNSAvacta to Present at Major European Conference
11th Oct 20187:00 amRNSAvacta's CTO to Present at Major US Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.